Myovant Sees Stock Soar After Rejecting $2.5B Takeover Bid
Stock in Swiss-based Myovant Sciences Ltd. jumped nearly 37% Monday after the biopharmaceutical company announced it had rejected as too low a $2.5 billion enterprise value offer from Japanese company and...To view the full article, register now.
Already a subscriber? Click here to view full article